- Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months
- The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression
- It is also expanding its ability to research novel compounds and develop IP for future commercialization
Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Chief Executive Officer (“CEO”) and Co-founder, Matt Stang, has been keen to note the company’s commitment to bringing psychedelic medicine closer to individuals dealing with mental health conditions, particularly those with treatment-resistant anxiety, depression, or post-traumatic stress disorder (“PTSD”).
“Based on our survey results, the majority of affected Americans believe that psychedelic medicine should be made available to patients with treatment-resistant anxiety, depression or PTSD,” he said. “Our mission to make these new, science-backed medicines accessible and affordable to a greater number of people suffering from these conditions is more urgent than ever,” he added (https://ibn.fm/dNoyn).
This drive has prompted the opening of two new Ketamine Wellness Centers (“KWC”) within the first quarter of 2022, bringing the total number of clinics to 13. These two new clinics, located in Salt Lake City and Reno, promise to offer affordable treatment to the residents of Utah, Nevada, and the larger California markets.
In addition, the urgency has also seen an increase in KWC offerings, with the introduction of the SPRAVATO(R) nasal spray as a treatment option. SPRAVATO is the first FDA-approved esketamine nasal spray targeted toward adults with treatment-resistant depression (“TRD”). This esketamine is designed to be taken together with an oral antidepressant and has proven effective for the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicide actions or thoughts.
The company is also expanding its ability to explore novel compounds and develop intellectual property (“IP”) for future commercialization. These efforts have seen the addition of a Health Canada 56 exceptions for MDMA, LSD, DMT, mescaline, 2C-B, and the acquisition of 60 grams of psilocybin mushrooms from nectar Health Sciences Laboratory Division Inc.
Over the next 18 months, Delic plans to open more state-of-the-art clinics, bringing affordable treatment alternatives closer to the people. It is also planning to delve deeper into more research while pushing for more approvals to present even more treatment options to patients with mental health ailments. “Delic is opening doors to a future with more effective medicines for a variety of mental health conditions with longer lasting benefits and less side effects,” noted Mr. Stang.
For more information, visit the company’s website at www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.